SecBot SecBot

KAPA

Kairos Pharma, LTD.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001962011 Biotech & Drug Discovery
$0.5432 +0.01 (+1.34%)
Oct 27 4:00 PM ET · prev $0.5360
Market cap
$1.8M
Nano cap
Median target
$7.00
+1189% · range $2.00–12.00
1 year
−93.3%
from $8.05 · Oct 27
30 days
−67.7%
from $1.68
52-week range
$0.5360–8.05
−93% from high · low Oct 26
Avg volume 20D
981.2K
Oct 6 spike 9.94M
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score
Strongest BULLISH Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) in metastatic…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.090 → −$0.090 over 90 days.

  • TrendDOWNTREND

    62% below its 50-day average. New closing low $0.5360 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM78,924$30.3K
GEODE CAPITAL MANAGEMENT, LLCADD111,290$62.2K
TWO SIGMA INVESTMENTS, LPDOUBLED94,008$66.7K
BANK OF AMERICA CORP /DE/TRIM134$95.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED65,800$77.0K
UBS Group AGTRIM5,979$7.0K
BANK OF AMERICA CORP /DE/DOUBLED304$356.00
UBS Group AGDOUBLED9,458$6.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Nov 2025
12-month targets · 2 analysts

Price is below the lowest target. Median implies +1189%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Nov 19, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Nov 4, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Oct 20, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Oct 7, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Sep 19, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Jul 16, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
−$0.09
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.09-$0.09–-$0.09+0.0%$0.00
Next Q-$0.11-$0.11–-$0.11+0.0%$0.00
Current FY-$0.37-$0.37–-$0.37+0.0%$0.00
Next FY-$0.67-$0.67–-$0.67+0.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) in metastatic castration-resistant…
8-K — Impact 6/10
Jul 22, 2026 SEC
Kairos Pharma entered into an Investigator Initiated Research (IIR) agreement with Bayer, under which Bayer will…
8-K — Impact 4/10
Jul 15, 2026 SEC
Kairos Pharma announced interim safety data from its Phase 1 trial of ENV-105 + osimertinib in EGFR-mutated NSCLC…
8-K — Impact 4/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
78,924 shares ($30.3K)
Mar 31, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
111,290 shares ($62.2K)

SecBot reports

6 filings · 2 bullish · 0 bearish · 4 neutral
All KAPA filing & press-release reports (6)